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1. Introduction
  Tuberculosis (TB) still remains one of the most common 
infectious diseases in developing countries. According to 
WHO reports, there were an estimated 8.7 million incident 
cases of TB globally[1]. Among of these cases, 3.7% are 
estimated to have multidrug resistant tuberculosis (MDR-
TB)[1]. Iran, one of the eastern Mediterranean countries, 
is located between the high MDR-TB (Azerbaijan and 
Armenia) and high-TB burden (Afghanistan and Pakistan) 
countries in the region. Since 1996, when the national TB 
control programs established in Iran, TB incidence has 
been declining from 34 per 100 000 to 21 per 100 000 cases 
in 2011[2]. However, in recent years, emergence and spread 
of MDR-TB threaten the TB control strategy. In many 
low- and middle-income countries, due to inadequate 
laboratory capacity, most of the patients with MDR-TB are 
not diagnosed. Treatment in these cases mostly failed and 
significant expenditure of health care resources is needed. 
The diagnosis of MDR-TB requires that TB patients are 
tested for susceptibility to anti-TB drugs[1]. Hence, early 
diagnosis of the disease and drug susceptibility testing of 
TB cases is essential priorities for TB care and control[1]. 
Though drug resistance patterns of Mycobacterium 
tuberculosis (MTB) has been previously reported from Iran, 
most of available information is localized and comparative 
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phenotypic analyses of MTB isolates from different parts of 
Iran were not performed[3,4]. The present study was hence 
designed to determine drug resistance pattern of MTB 
isolates from 5 provinces of Iran including Tehran (the 
capital of Iran), Sistan-Baluchestan (southeast province of 
Iran with highest rate of TB), Kermanshah (western part of 
Iran, bordering with Iraq), Hormozgan (southern part of Iran 
and highly endemic for malaria) and Isfahan (located on the 
main north-south and east-west routes crossing Iran).
2. Materials and methods
2.1. Study population and samples
  The study was approved by the Local Ethical Committee. 
The study was conducted over a 2-year of period (from 
March 2010 to June 2012) in the TB centers of 5 provinces 
of Iran that covers Eastern to the Western regions of the 
country. The study was cross-sectional that was performed 
single blinded. A total of 6 426 clinical specimens were 
obtained from TB suspected patients attending the 5 different 
TB center including Tehran (n=2 133), Sistan-Baluchestan 
(n=873), Kermanshah (n=377), Hormozgan (n=1 538) and 
Isfahan (n=1 505). Patients had clinical signs and symptoms 
of TB and undergoing examination for possible active TB.
  The age of patients ranged from 11 to 80 years and the 
mean age of the patients was 45 years. Based on history and 
clinical examination, none of the patients had documented 
HIV infection. 
  In the each TB centers, 3 samples of sputum and other 
specimens (Pleural fluid, wound, urine and CSF) were 
collected on sterile containers from each patient for 
microscopy and culture tests. All specimens were held at 
4 曟 until processed by standard laboratory procedures[5]. 
The majority of specimens were processed within 24 h at TB 
laboratory.  
2.2. Identification of mycobacteria
  For microscopy examination, a smear from samples using 
a wire loop was made on clean slide. The smear was stained 
by Ziehl Neelsen method. Known negative and positive slide 
were prepared with every batch of the specimens. Samples 
from each patient were decontaminated by Petroff’s method 
and were inoculated into Lowenstein-Jensen (LJ) media 
(Merck)[6]. The slope cultures were incubated at 37 ℃ and 
examined for growth once weekly up to 6 weeks. Each isolate 
was examined regarding morphology, pigmentation and date 
of growth. Bacterial isolates identified as MTB complex using 
standard biochemical tests, including production of niacin, 
nitrate reduction, catalase and inhibition by thiophene-2-
carboxylic acid hydrazide[7,8]. Isolates of MTB cultured from 
patients of each province were sent to mycobacteriology 
center, Baqiyatallah hospital, Tehran, for confirmation and 
susceptibility testing.
2.3. Drug susceptibility testing
  Drug susceptibility of isolates to first-line anti-TB drugs 
was determined using the proportion method on Lowenstein-
Jensen medium[7]. Resistance was expressed as the 
percentage of colonies that grew on critical concentrations 
of the drugs: 0.2 毺g/mL for isoniazid (INH), 2.0 毺g/mL for 
ethambutol (EMB), 4 毺g/mL for streptomycin (STM) and 
40 毺g/mL for rifampicin (RMP). Interpretation was made 
according to the usual criteria for resistance, ie., 1% for 
all drugs. We used the protocols of quality control in our 
laboratories which are mentioned in different sources[7,9].
2.4. Definition
  Any drug resistance was defined as resistance to one or 
more first-line anti-TB drugs. Monoresistance was defined 
as resistance to only one of the four first-line anti-TB drugs 
(INH, RMP, EMB and STM). MDR was defined as MTB strains 
that were resistant to at least INH and RMP. 
  Primary resistance (resistance among new TB cases) was 
defined as in vitro resistance in patients who did not have 
a history of anti-TB treatment, while secondary resistance 
(resistance among previously treated cases) was defined as 
in vitro resistance in patients previously treated with anti-
TB drugs.
2.5. Statistical analysis 
  Statistical analysis was carried out using SPSS version 
18. Prevalence was reported by 95% confidence intervals 
(CI). Comprasion of propotion was done by Chi squere 
test. P values less than 0.05 were considered statistically 
significant.
3. Results
  Of 6 426 clinical specimens, 261 culture were mycobacteria 
positive, of which 252 were MTB [Tehran (n=85), Sistan-
Baluchestan (n=59), Kermanshah (n=15), Hormozgan (n=48) 
and Isfahan (n=45)] and 9 were MOTT (mycobacteria other 
than tuberculosis). Of 252 MTB isolates, two hundred and 
thirty-three were from pulmonary sites [Sputum (n= 136) 
and bronchoalveolar lavage (n=97)] while 19 isolates were 
from extra-pulmonary sites [Pleural fluid (n=5), wound 
(n=6), urine (n=5) and CSF (n=3)]. Also based on patients 
information, all MTB cultured was from new cases. 
3.1. Drug susceptibility patterns
  Of 252 MTB isolates for whom drug susceptibility testing 
was performed, 211 (83.7%, 95% CI = 79.1%-88.2%) were 
pan-susceptible and 41 (16.3%, 95% CI = 11.7%-20.8%) 
were resistant to at least one drug. The majority of drug 
resistant isolates showed resistance to STM (12.0%, n=30, 
95% CI=16%-8%) followed by INH (8.0%, n=20, 95% CI=4.6%-
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11.3%), RMP (6.0%, n=15, 95% CI=3%-9%) and EMB (5.5%, 
n=14, 95% CI=2.6%-8.3%) (Table 1).
  Among the investigated isolates from different parts 
of Iran, 16 (6.3%, 95% CI=3.3%-9.2%) MTB isolates were 
MDR. A clear evidence of heterogeneity amongst the 5 
provinces in the proportions with resistance to one or more 
drugs was observed [χ² = 12.209 (4 degrees of freedom), P 
values=0.015 9]. Complete drug resistance patterns of MTB 
isolates are shown in Table 1. 
4. Discussion
  In the last decades, by running the national TB control 
program in Iran, TB incidence has been decreased. However, 
emergence and spread of MDR-TB has threaten the national 
TB control programs. Drug susceptibility testing for TB 
patients is one of the most effective tools of control and 
management of MDR-TB. 
  In the present study, 41 (16.3%) of 252 MTB isolates collected 
from patients of different parts of Iran were resistant to at 
least one or more anti-TB drugs. This observation indicating 
lower any drug resistance than studies conducted in Turkey, 
Iraq and Pakistan with any drug resistance rates of 21.1%, 
29.7% and 64% respectively[10-12]. According to WHO reports 
in the year 2011, Iran has a lower incidence of TB (21 per
100 000 population) than the all of neighboring countries 
(Turkey: 24 per 100 000, Iraq: 45 per 100 000, Armenia: 55 per 
100 000, Azerbaijan: 113 per 100 000, Afghanistan: 189 per 
100 000 and  Pakistan: 231 per 100 000)[2].
  The lower number of new cases in Iran and subsequently 
lower amount of previous anti-TB drug taking may explain 
the lower any drug resistance in this study.
  Drug resistance to STM (12.0%) was found to be the highest 
proportion among anti-TB drugs, followed by INH (8.0%) 
which is consistent with previous reports from Iran[13-16]. 
The cause of the high rates of primary drug resistance to 
STM and INH in MTB isolates from new cases is difficult to 
explain. The high prevalence of STM resistance isolates may 
be due to previous usage of other aminoglycosidal drugs for 
treatment of different infectious diseases like brucellosis 
that resulting in cross-resistance[14,17]. Also, widespread use 
of STM in the past for treatment of the brucellosis, a disease 
that is endemic in Iran may explain another reason of high 
rate of STM resistance. This high rate of STM resistance has 
very important implications for TB control strategies as it 
would make treatment regimes less effective. Definitive 
studies have not been performed to determine the best 
treatment for different patterns of drug resistance. However, 
to prevent treatment failure, recommended regimes that 
suggested by WHO should be given to TB patients[18].
  As reported by other studies, we found that Monoresistance 
RMP was rare and most of the RMP resistant strains were 
also INH resistant. Thus RMP resistance would be a good 
marker for the identification of MDR-TB[13].
  As reported by the WHO International Project in 79 
countries worldwide over 1999-2002, MDR-TB was found in 
1.1% of new cases in Iran[19]. A recent study from National 
Research Institute of Tuberculosis and Lung Disease in 
Iran, that presented drug resistance patterns of TB from 
2003 to 2008, has shown that 2% of MTB isolates from new 
cases were MDR[20]. Prevalence of MDR-TB in Iran, in the 
year 2011, was 5% for new cases as reported by WHO[2]. Our 
result shows a little higher percentage of MDR-TB (6.3%), 
compared to WHO data and other studies of Iran[14,16,20]. 
This supports the idea of inadequacy in TB infection control 
programs and irregular treatments during recent years. Drug 
susceptibility testing for all new cases to provide optimal 
treatment is strongly recommended to avoid the emergence 
of MDR-TB. The rate of drug resistance in Kermanshah and 
Sistan-Baluchestan was in comparable with the studies 
conducted in other provinces of Iran[4,21]. Bordering with the 
high levels of drug resistance countries (Iraq and Pakistan) 
and possible transmission of MDR-TB may explain the 
rate of drug resistance in these provinces. Screening all 
immigrants at border of entry from these counties could 
contribute to national TB control program in Iran.
  Hormozgan, a province on the Persian Gulf coast, is 
highly endemic for malaria[22]. The rate of MDR-TB in 
this province was relatively higher than what was reported 
in other studies[4]. Interactions between TB and malaria 
have been demonstrated previously by authors. Malaria 
infection affects severely ill TB patients and exacerbates 
mycobacterial infection[23-26]. Moreover, the respiratory 
distress that is frequent during acute malaria can worsen 
the respiratory effort related to TB[27]. Therefore, given the 
multiple interactions between malaria and TB, public health 
strategies for prevention and management of these infectious 
Table 1
Resistance to first-line drugs among MTB isolates from different parts of Iran.
Type Tehran No (%) Sistan-Baluchestan No (%) Kermanshah No (%) Hormozgan No (%) Isfahan No (%) Total No (%)
Strains   85 (33.7)   59 (23.4) 15 (5.4)  48 (19.0)  45 (17.8) 252 (100.0) 
Pan-susceptible   68 (80.0)   49 (83.0)     9 (60.0)  42 (87.5)  43 (20.0) 211 (83.7)
Any drug resistance   17 (20.0)   10 (17.0)     6 (40.0)    6 (12.5)   2 (3.2)   41 (16.3)
INH   6 (7.0)   5 (8.4)     4 (26.6)   3 (6.2)   2 (7.1) 20 (8.0)
RMP   7 (8.2)   3 (5.0)     3 (20.0)   2 (4.1)   2 (8.6) 15 (6.0)
EMB   6 (7.0)   3 (5.0)     3 (20.0)   2 (4.1)   0 (0.0) 14 (5.5)
STM   14 (16.4)     8 (13.5)     3 (20.0)   4 (8.3)   1 (2.2)   30 (12.0)
Monoresistance   11 (13.0)     7 (11.8)     2 (13.3)   4 (8.3)   0 (0.0) 24 (9.5)
Multidrug resistance   6 (7.0)   3 (5.0)     3 (20.0)   2 (4.1)     2 (11.7) 16 (6.3)
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diseases should be investigated.
  In conclusion, the prevalence of drug resistance in this 
study area was relatively high comparable to WHO data 
and previous studies, underscoring the need for greater 
enforcement of TB control strategies in the country. Drug 
susceptibility testing for all TB cases to provide optimal 
treatment, establishing advanced diagnostic facilities for 
rapid detection of MDR-TB, continuous monitoring of drug 
resistance and control of drug resistant TB at border entry 
points with high-TB burden countries are recommended for 
prevention and control of drug-resistant TB.
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